NCT04367883 Influenza Vaccination, ACEI and ARB in the Evolution of SARS-CoV2 Infection
| NCT ID | NCT04367883 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Consorci Sanitari de Terrassa |
| Condition | COVID19 |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2020-03-01 |
| Primary Completion | 2025-01-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 2020-03-01 with a primary completion date of 2025-01-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. Other authors described how none of the elderly patients receiving antihistamines and azythromycin in two nursing homes in Toledo -Spain- during the first wave died or needed hospital admission, even considering that 100% of residents had a positive serological test after that wave. Other authors have described a positive evolution in patients receiving amantadine for their Parkinson's disease. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving these treatments showed a better evolution.
Eligibility Criteria
Inclusion Criteria: * Hospital Admissions at the Hospital of Terrassa from March 1, 2020 for any cause. Exclusion Criteria: * None. * For comparison of percentage of Influenza vaccination, ACEI and ARB vs general population, patients from outside the reference area of the Terrassa Health Consortium would be excluded.
Contact & Investigator
Anna Puigdellívol-Sánchez, Ph D
PRINCIPAL INVESTIGATOR
Consorci Sanitari de Terrassa
Frequently Asked Questions
Who can join the NCT04367883 clinical trial?
This trial is open to participants of all sexes, studying COVID19. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04367883 currently recruiting?
Yes, NCT04367883 is actively recruiting participants. Contact the research team at apuigdellivol@cst.cat for enrollment information.
Where is the NCT04367883 trial being conducted?
This trial is being conducted at Terrassa, Spain.
Who is sponsoring the NCT04367883 clinical trial?
NCT04367883 is sponsored by Consorci Sanitari de Terrassa. The principal investigator is Anna Puigdellívol-Sánchez, Ph D at Consorci Sanitari de Terrassa. The trial plans to enroll 3,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.